Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 692795, 11 pages
Research Article

Effect and Potential Mechanism of Electroacupuncture Add-On Treatment in Patients with Parkinson’s Disease

1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China
2Department of Acupuncture, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China
3Department of Physiology, Capital Medical University, Beijing 100069, China
4Department of Geriatrics, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China
5Key Laboratory for Neurodegenerative Disorders of the Ministry of Education, Beijing 100069, China
6Center of Parkinson’s Disease, Beijing Institute for Brain Disorders, Beijing 100053, China
7China National Clinical Research Center for Neurological Diseases, Beijing 100050, China
8Beijing Key Laboratory on Parkinson’s Disease, Beijing 100053, China

Received 15 March 2015; Accepted 28 July 2015

Academic Editor: Andreas Sandner-Kiesling

Copyright © 2015 Fang Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objectives. To explore effectiveness and mechanisms of electroacupuncture (EA) add-on treatment in Parkinson’s disease (PD) patients. Methods. Fifty PD patients were randomly assigned to drug plus EA (D + EA) group and drug alone (D) group. Subjects in D + EA group received stimulation in points of bilateral fengfu, fengchi, hegu, and central dazhui. Participants were evaluated by scales for motor and nonmotor symptoms. Levels of neuroinflammatory factors and neurotransmitters in serum were detected. Results. EA add-on treatment remarkably reduced scores of Unified Parkinson’s Disease Rating Scale (UPDRS) III and its subitems of tremor, rigidity, and bradykinesia and conspicuously decreased UPDRS III scores in patients with bradykinesia-rigidity and mixed types and mild severity. Depression and sleep disturbances were eased, which were reflected by decreased scores of Hamilton Depression Rating Scale, Pittsburgh Sleep Quality Index, and elevated noradrenaline level. Effects of EA add-on treatment on motor symptoms and sleep disturbances were superior to drug alone treatment, markedly improving life quality of PD patients. EA add-on treatment decreased nitric oxide level in serum. Conclusions. EA add-on treatment is effective on most motor symptoms and some nonmotor symptoms and is particularly efficacious in PD patients at early stage. Antineuroinflammation may be a mechanism of EA add-on treatment.